Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection

• Erin Logan,
• Angelique Kany Kany Luabeya,
• Angelique Kany Kany Luabeya,
• Humphrey Mulenga,
• Humphrey Mulenga,
• Dunja Mrdjen,
• Cynthia Ontong,
• Cynthia Ontong,
• Adam F. Cunningham,
• Michele Tameris,
• Michele Tameris,
• Helen McShane,
• Thomas J. Scriba,
• Thomas J. Scriba,
• William G. C. Horsnell,
• William G. C. Horsnell,
• William G. C. Horsnell,
• Mark Hatherill,
• Mark Hatherill

Affiliations

Erin Logan

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Angelique Kany Kany Luabeya

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Angelique Kany Kany Luabeya

South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa

Humphrey Mulenga

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Humphrey Mulenga

South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa

Dunja Mrdjen

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Cynthia Ontong

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Cynthia Ontong

South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa

Adam F. Cunningham

Institutes of Immunology and Immunotherapy and Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom

Michele Tameris

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Michele Tameris

South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa

Helen McShane

The Jenner Institute, University of Oxford, Oxford, United Kingdom

Thomas J. Scriba

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Thomas J. Scriba

South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa

William G. C. Horsnell

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

William G. C. Horsnell

Institutes of Immunology and Immunotherapy and Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom

William G. C. Horsnell

Laboratory of Molecular and Experimental Immunology and Neurogenetics, UMR 7355, Le Studium Institute for Advanced Studies, CNRS-University of Orléans, Orléans, France

Mark Hatherill

Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa

Mark Hatherill

South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa